No Data
Shengnuo Bio (688117.SH): The project for Teirbo peptide Active Pharmaceutical Ingredient and formulation is currently in the pharmaceutical research stage.
Gelonghui reported on December 26 that Shengnuo Bio (688117.SH) stated on the investor interaction platform that the Active Pharmaceutical Ingredient and injection project for Semaglutide is currently in the pharmaceutical research stage, and the Active Pharmaceutical Ingredient for Semaglutide has been filed with the USA FDA. The project for the Active Pharmaceutical Ingredient and formulation of Teriparatide is also currently in the pharmaceutical research stage.
Shengnuo Biotechnology (688117.SH): Lepu Medical Technology has cumulatively reduced its shareholding by 0.7912%.
On December 26, Gelonghui reported that Shengnuo Biology (688117.SH) announced that the company recently received a notification letter from Lepu Medical Technology regarding the results of shareholding reduction. As of the date of this announcement, Lepu Medical Technology has cumulatively reduced its shareholding by 889,445 shares through centralized bidding, accounting for 0.7912% of the company's total share capital. After the reduction, Lepu Medical Technology holds 5,272,000 shares of the company, accounting for 4.6896% of the company's total share capital, and this shareholding reduction plan has reached its expiration.
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Shengnuo Biotech: Third Quarter Report 2024
Third Quarter Report 2024
ChengDu ShengNuo Biotec's Nine-Month Profit Seen to Surge Up to 76%
What ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) 30% Share Price Gain Is Not Telling You
No Data
